Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stealth Peptides Inc.
ClinicalTrials.gov Identifier:
NCT01513200
First received: January 6, 2012
Last updated: April 17, 2012
Last verified: April 2012
  Purpose

This will be a phase 1 randomized, double-blind crossover trial enrolling approximately 12 healthy volunteers to assess whether intravenous (IV) UFH and IV Bendavia administered together have any significant impact on the pharmacodynamic effects of UFH and the pharmacokinetics of Bendavia.


Condition Intervention Phase
Healthy Volunteers
Drug: Unfractionated heparin (UFH)
Drug: Bendavia
Drug: Saline (0.9%, sterile, for infusion)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Two Part Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers and the Effects of Bendavia™ and Unfractionated Heparin When Administered Concurrently

Resource links provided by NLM:


Further study details as provided by Stealth Peptides Inc.:

Primary Outcome Measures:
  • Mean difference over 24 hours in aPTT (activated partial prothrombin time) in seconds when UFH is administered with and without Bendavia [ Time Frame: Pre-UFH to 24 hours post-study drug administration ] [ Designated as safety issue: Yes ]

    Difference in group (with/without Bendavia) means of aPPT values will be assessed for statistical significance (Analysis of Variance; ANOVA) at the following time points:

    Pre-UFH, Pre-Study-Drug infusion start and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours Post-Study-Drug infusion start.



Secondary Outcome Measures:
  • Mean difference over 12 hours of anti-factor Xa (IU/mL) when UFH is administered with and without Bendavia [ Time Frame: Pre-UFH to 12 hours post-study drug administration ] [ Designated as safety issue: Yes ]

    Difference in group (with/without Bendavia) means of aPPT values will be assessed for statistical significance (ANOVA) at the following time points:

    Pre-UFH, Pre-Study-Drug infusion start and 4, 8 and 12 hours Post-Study-Drug infusion start.


  • Mean difference in Bendavia Area Under the Curve(0-infinity) (AUC) when Bendavia is administered with and without UFH (historical data will be used to provide bendavia without UFH) [ Time Frame: 48 hours post-study-drug administration ] [ Designated as safety issue: No ]
  • Difference in number of adverse events when UFH is administered with and without Bendavia [ Time Frame: Pre-dose through Day 10 ] [ Designated as safety issue: Yes ]
    Adverse events will be described by treatment group (UFH with and without Bendavia). No statistical analysis of the difference between AEs will be conducted.


Enrollment: 12
Study Start Date: January 2012
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: UFH + Placebo
UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
Drug: Unfractionated heparin (UFH)
UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
Drug: Saline (0.9%, sterile, for infusion)
Saline (placebo) Constant IV infusion for 4 hours
Experimental: UFH + Bendavia
UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
Drug: Unfractionated heparin (UFH)
UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
Drug: Bendavia
Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult males or females aged between 18 and 65 years of age with signed informed consent.
  • Women who are not post-menopausal (without menstrual bleed for >24 months) or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment with understanding (through informed consent process) to not become pregnant over the duration of the study and must agree to employ an effective form of birth control for the duration of the study [Acceptable forms of birth control are: double-barrier contraceptives (condom, diaphragm with spermicide) or intra-uterine device (IUD) 1 week prior to and at least 30 days post treatment even if hormonal contraceptives are used]

Exclusion Criteria:

  • Serum sodium level below the lower limit of the site's clinical laboratory normal range at both study period qualification visits,
  • Platelet value below the lower limit of normal range at screening or admission,
  • aPTT value outside the normal range at screening or admission,
  • Creatinine clearance calculated by the Cockcroft and Gault method calculated to be <90 mL/min for males and <80 mL/min for females,
  • Any addition laboratory abnormalities determined as clinically significant by the Principal Investigator at laboratory screening,
  • Clinically significant abnormalities on physical examination,
  • Body Mass Index (BMI) of less than 18 kg/m2 or greater than 32 kg/m2,
  • Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems,
  • History of seizures or history of epilepsy,
  • History of serious (Principal Investigator judgment) mental illness,
  • Receipt of investigational medicinal product within 30 days before planned date of unfractionated heparin and/or study drug administration,
  • Positive serology for human immunodeficiency virus 1 or 2 (HIV1 or 2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV),
  • Fever greater than 37.5°C at the time of planned dosing,
  • Suspicion of or recent history of alcohol or substance abuse,
  • Donated blood or blood products within the past 30 days,
  • Women who are pregnant or breastfeeding,
  • Employee or family member of the investigational site,
  • Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products or who have used any tobacco products in the 30 days prior to screening,
  • Subjects who are either unwilling to agree to refrain from using or found to be using:

    1. Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement period
    2. Prescription medications from 14 days prior to and 7 days post treatment (excluding hormonal contraceptives)
    3. Hormonal contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to and 30 days post treatment
  • Subjects taking aspirin or any other non-steroidal anti-inflammatory agent, either prescription or over-the-counter, within 10 days of treatment,
  • Subjects known to have allergic or untoward effects when using unfractionated heparin,
  • Subjects having previous exposure to Bendavia,
  • Subjects who are expected to undergo any surgical procedure within 14 days of the completion of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01513200

Locations
United States, Florida
Clinical Pharmacology of Miami
Miami, Florida, United States, 33014-3616
Sponsors and Collaborators
Stealth Peptides Inc.
Investigators
Principal Investigator: Kenneth C Lasseter, MD Clinical Pharmacology of Miami
Study Director: Richard Straube, MD Stealth Peptides
  More Information

No publications provided

Responsible Party: Stealth Peptides Inc.
ClinicalTrials.gov Identifier: NCT01513200     History of Changes
Other Study ID Numbers: SPIRI-155
Study First Received: January 6, 2012
Last Updated: April 17, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Calcium heparin
Heparin
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014